There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Petros Pharmaceuticals (PTPI – Research Report), Athira Pharma (ATHA – Research Report) and Haemonetics (HAE – Research Report) with bullish sentiments.
Petros Pharmaceuticals (PTPI)
Maxim Group analyst Naz Rahman maintained a Buy rating on Petros Pharmaceuticals on January 17 and set a price target of $4.00. The company’s shares closed last Monday at $1.24, close to its 52-week low of $0.92.
According to TipRanks.com, Rahman has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Petros Pharmaceuticals with a $4.00 average price target.
See the top stocks recommended by analysts >>
Athira Pharma (ATHA)
In a report issued on January 18, Thomas Shrader from BTIG maintained a Buy rating on Athira Pharma, with a price target of $10.00. The company’s shares closed last Monday at $2.98.
According to TipRanks.com, Shrader is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Athira Pharma with a $11.33 average price target, representing a 288.0% upside. In a report issued on January 3, JMP Securities also reiterated a Buy rating on the stock with a $19.00 price target.
Haemonetics (HAE)
In a report issued on January 19, Michael Petusky from Barrington maintained a Buy rating on Haemonetics, with a price target of $105.00. The company’s shares closed last Monday at $83.97.
According to TipRanks.com, Petusky is a 4-star analyst with an average return of
Currently, the analyst consensus on Haemonetics is a Strong Buy with an average price target of $106.25.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PTPI:
